US20200390930A1 - Systems and methods for treating a wound with wound packing - Google Patents
Systems and methods for treating a wound with wound packing Download PDFInfo
- Publication number
- US20200390930A1 US20200390930A1 US16/798,180 US202016798180A US2020390930A1 US 20200390930 A1 US20200390930 A1 US 20200390930A1 US 202016798180 A US202016798180 A US 202016798180A US 2020390930 A1 US2020390930 A1 US 2020390930A1
- Authority
- US
- United States
- Prior art keywords
- wound
- packing
- plasma
- cells
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012856 packing Methods 0.000 title claims abstract description 130
- 238000000034 method Methods 0.000 title abstract description 57
- 210000002381 plasma Anatomy 0.000 claims abstract description 78
- 210000002894 multi-fate stem cell Anatomy 0.000 claims abstract description 71
- 210000004623 platelet-rich plasma Anatomy 0.000 claims abstract description 4
- 239000002562 thickening agent Substances 0.000 claims description 27
- 210000002798 bone marrow cell Anatomy 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 abstract description 59
- 108010035532 Collagen Proteins 0.000 abstract description 59
- 229920001436 collagen Polymers 0.000 abstract description 59
- 210000004027 cell Anatomy 0.000 abstract description 34
- 210000001185 bone marrow Anatomy 0.000 abstract description 15
- 239000012634 fragment Substances 0.000 abstract description 15
- 230000004888 barrier function Effects 0.000 abstract description 14
- 230000001681 protective effect Effects 0.000 abstract description 14
- 108090000190 Thrombin Proteins 0.000 abstract description 12
- 229960004072 thrombin Drugs 0.000 abstract description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 7
- 239000001110 calcium chloride Substances 0.000 abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 7
- 210000004381 amniotic fluid Anatomy 0.000 abstract description 4
- 210000001691 amnion Anatomy 0.000 abstract description 3
- 210000000130 stem cell Anatomy 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 193
- 206010052428 Wound Diseases 0.000 description 191
- 210000003491 skin Anatomy 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 210000004207 dermis Anatomy 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 210000002469 basement membrane Anatomy 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000002356 single layer Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000243251 Hydra Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010048031 Wound dehiscence Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00004—Non-adhesive dressings
- A61F13/00021—Non-adhesive dressings characterized by the structure of the dressing
- A61F13/00029—Non-adhesive dressings characterized by the structure of the dressing made of multiple layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A61F13/01029—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0033—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0095—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
Definitions
- the present invention relates to systems and methods for treating a wound.
- some implementations of the present invention relate to methods for forming a wound packing comprising multi-potent cells (e.g., bone marrow cells), plasma, collagen, and/or a thickening agent.
- multi-potent cells e.g., bone marrow cells
- plasma e.g., plasma
- collagen e.g., collagen
- thickening agent e.g., collagen
- skin seeds are optionally applied to a surface of the packing and a protective barrier is applied over the packing.
- sores, ulcers, and other wounds can dramatically affect an individual's life, limiting the individual's ability to move (e.g., walk), work, and play.
- such wounds can cause pain and take an emotional toll on the individual, costing the individual and/or others relatively large amounts of money, energy, and time spent in, and for, recovery.
- sores, ulcers, and other wounds can lead to amputation, which can dramatically complicate life, be physically and emotionally draining, increase healthcare costs, and otherwise be extremely undesirable.
- the present invention relates to systems and methods for treating a wound.
- some implementations of the present invention relate to methods for forming a wound packing comprising multi-potent cells (e.g., bone marrow cells), plasma, collagen, and/or a thickening agent.
- multi-potent cells e.g., bone marrow cells
- plasma e.g., plasma
- collagen e.g., collagen
- thickening agent e.g., collagen
- skin seeds are optionally applied to a surface of the packing and a protective barrier is applied over the packing.
- the described methods can comprise any suitable step or characteristic
- the described methods include combining multi-potent cells (e.g., cells from bone marrow, amniotic tissue, amniotic fluid, placental tissue, fat tissue, umbilical cord tissue, stem cells, and/or any other suitable source) with plasma (e.g., platelet rich plasma, concentrated plasma, super concentrated plasma, plasma, and/or any other suitable type of plasma), and collagen (e.g., native collagen, organized reconstituted collagen, collagen, and/or any other suitable type of collagen).
- the various components are formed into a shape that substantially corresponds to the shape of a wound.
- thrombin, calcium chloride, one or more serine proteases, and/or any other suitable thickening agent or agents are combined with the multi-potent cells, plasma, and/or collagen to coagulate, gel, and/or otherwise harden the components to form a wound packing.
- the wound packing is inserted into or otherwise applied to a wound (e.g., a wound that has been cleaned, debrided, disinfected, had necrotic tissue removed, that is bleeding, and/or that is otherwise ready to receive the packing).
- a wound e.g., a wound that has been cleaned, debrided, disinfected, had necrotic tissue removed, that is bleeding, and/or that is otherwise ready to receive the packing.
- skin seeds or skin graft fragments (e.g., micronized and/or otherwise fragmented epidermal and/or dermal tissue) are applied to the wound packing (e.g., an outer surface of the wound packing).
- the wound, wound packing, and skin cells are covered with a protective barrier.
- barriers include a single layer protective membrane, such as a layer of a-cellular dermis (e.g., human a-cellular dermis, animal dermis, etc.), a layer of silicon (e.g., one or more layers of a surgical silicone), and/or any other suitable single layer membrane; a bilayer protective membrane, such as a piece of an a-cellular dermis with a basement membrane, a piece of an a-cellular dermis comprising a layer of surgical silicone, and/or any other suitable bi-layer membrane; and/or any other suitable membrane comprising two or more layers.
- a single layer protective membrane such as a layer of a-cellular dermis (e.g., human a-cellular dermis, animal dermis, etc.), a layer of silicon (e.g., one or more layers of a surgical silicone), and/or any other suitable single layer membrane
- a bilayer protective membrane such as a piece of an a-cellular dermis with a basement membrane, a piece
- the wound is dressed further. While the wound can be dressed in any suitable manner, in some cases, the wound is dressed with: gauze, a bandage, a wrap, a total contact cast, a non-weight-bearing cast or dressing, a wound veil, a contact layer flex bandage, a compressive dressing, KERLIXTM wrapping, an absorbent abdominal pad, calcium alginate, a hydra fiber, a fenestrated gauze drain sponge, a TRIACTTM treatment (e.g., produced by Hollister of Libertyville, Ill., USA), an ointment, a petroleum-based jelly, and/or with any other suitable type of wound dressing.
- gauze e.g., a bandage, a wrap, a total contact cast, a non-weight-bearing cast or dressing, a wound veil, a contact layer flex bandage, a compressive dressing, KERLIXTM wrapping, an absorbent abdominal pad, calcium alginate, a hydra fiber,
- the wound packing lacks multi-potent cells, while still comprising plasma and collagen. In some other implementations, the wound packing lacks collagen. In still other non-limiting implementations, the wound packing is used without the application of skin seeds to an external surface of the packing. In still other implementations, one or more components of the wound packing (e.g., the multi-potent cells, the plasma, skin seeds, etc.) are autologous to the person to which the wound packing is to be applied. In yet other implementations, however, one or more components of the wound packing are autologous, allogeneic, xenogeneic, and/or syngeneic to the person to which the wound packing is to be applied.
- While the described systems and methods may be particularly useful in the area of treating one or more sores, ulcerations, and/or other wounds on the sole (and other portions) of an individual's foot, those skilled in the art can appreciate that the described systems and methods can be used in a variety of different applications and in a variety of different areas of manufacture to treat a wide range of injuries, in any suitable location, including, without limitation, injuries to an individual's arm, hand, finger, toe, leg, thigh, calf, buttocks, back, torso, abdomen, neck, head, face, etc.).
- the described systems and methods are used to treat surgical wounds, bed sores, pressure ulcers, wound dehiscence, graft donor sites, lesions, sores, vascular ulcers, diabetic ulcers (including, without limitation, diabetic foot ulcers), trauma wounds, tears, tunneling wounds, abrasions, sores, lacerations, and/or other wounds.
- FIG. 1 illustrates a flowchart depicting a method for forming a wound packing in accordance with a representative embodiment
- FIGS. 2A-2D each illustrate a cross-sectional view of a different representative embodiment of the wound packing
- FIG. 3 illustrates a flowchart depicting a method for treating a wound with the wound packing in accordance with a representative embodiment
- FIG. 4 illustrates a cross-sectional view of the wound packing applied to a wound in accordance with a representative embodiment.
- the present invention relates to systems and methods for treating a wound.
- some implementations of the present invention relate to methods for forming a wound packing comprising multi-potent cells (e.g., bone marrow cells), plasma, collagen, and/or a thickening agent.
- multi-potent cells e.g., bone marrow cells
- plasma e.g., plasma
- collagen e.g., collagen
- thickening agent e.g., collagen
- skin seeds are optionally applied to a surface of the packing and a protective barrier is applied over the packing.
- FIG. 1 illustrates a representative embodiment of a method 100 for forming the described wound packing. While such method 100 (and all other methods describe herein) can be modified in any suitable manner (e.g., with any suitable portion of the method being omitted, added to, reordered, performed simultaneously with another portion of the method, performed independently, substituted with another technique, and/or otherwise being modified in any suitable manner), step 105 in FIG. 1 shows that, in some embodiments, the method 100 includes obtaining multi-potent cells.
- the multi-potent cells can comprise any suitable cells that are capable of differentiating and helping a wound to which they are applied to heal.
- the term multi-potent cells may be used herein to refer to cells that are totipotent, pluripotent, and/or multipotent.
- Some non-limiting examples of such cells include bone marrow cells, mesenchymal cells, stem cells, neural stem cells, cells from amniotic fluid, placental cells, amniotic membrane cells, and/or any other suitable unspecialized (e.g., multi-potent and/or undifferentiated) cells that can differentiate into specialized cells with specific functions that are useful in the wound packing.
- the multi-potent cells can be obtained from any suitable organism, including, without limitation, from the patient to whom the wound packing is to be applied (e.g., autologous cells), from one or more third-party individuals (e.g., allogenic cells), from an identical twin (e.g., syngeneic cells), from an animal of a different species (e.g., xenogeneic cells), etc.
- the multi-potent cells comprise autologous cells taken from the patient.
- the terms patient and individual (and variations thereof) may be used to refer to any person or other subject to whom the described wound packing can be applied.
- the multi-potent cells can be obtained from any suitable source, including, without limitation, from bone marrow (including, without limitation, mesenchymal cells), placental tissue, amniotic fluid, amniotic membrane tissue, umbilical cord tissue, brain tissues, blood vessels, skeletal muscle, skin, teeth, heart tissue, liver tissue, gut tissue, etc.
- the multi-potent cells can be obtained from any suitable location. Indeed, in some embodiments in which the multi-potent cells comprise bone marrow cells, the bone marrow cells are collected from one or more iliac crests, calcanei, sternums, lumbar vertebrae, femurs, tibias, and/or other suitable locations, from one or more individuals.
- the multi-potent cells can be obtained in any suitable manner, including, without limitation, via aspiration (e.g., with a bone marrow aspirate needle or otherwise), biopsy (e.g., trephine biopsy or otherwise), excision, and/or in any other suitable manner.
- the multi-potent cells comprise bone marrow aspirate taken from the iliac crest, calcaneus, sternum, and/or tibia of the patient to whom the wound packing is to be applied.
- the cells can be aspirated in any suitable manner, including, without limitation, via a bone marrow aspirate needle and syringe coated with a blood thinner (e.g., heparin, anti-coagulate citrate dextrose, and/or any other suitable thinner).
- a blood thinner e.g., heparin, anti-coagulate citrate dextrose, and/or any other suitable thinner.
- any suitable amount of material comprising multi-potent cells can be extracted from an organism (e.g., the patient). Indeed, in some embodiments in which the multi-potent cells comprise bone marrow cells, between about 1 and about 300 mls of bone marrow aspirate are initially collected. In other embodiments, any suitable amount of multi-potent cells (e.g., bone marrow aspirate) that falls in a sub-range (e.g., between about 40 mls and about 200 mls) of the aforementioned range can be extracted for use in formation in a sub-range (e.g., between about 40 mls and about 200 mls) of the aforementioned range can be extracted for use in formation in a sub-range (e.g., between about 40 mls and about 200 mls) of the aforementioned range can be extracted for use in formation in a sub-range (e.g., between about 40 mls and about 200 mls) of the aforementioned range can
- the multi-potent cells are optionally concentrated for inclusion in the wound packing.
- the multi-potent cells e.g., bone marrow cells
- the multi-potent cells can be concentrated in any suitable manner, including, without limitation, via a conventional or novel cell concentration kit (e.g., a BIOCUETM kit, produced by Biomet Biologics, LLC of Warsaw, Ind., USA) centrifugation, filtration, separation, and/or any other conventional or novel technique that is suitable for concentrating cells for use in the wound packing.
- a conventional or novel cell concentration kit e.g., a BIOCUETM kit, produced by Biomet Biologics, LLC of Warsaw, Ind., USA
- the multi-potent cells are concentrated through centrifugation.
- the centrifugation can be performed in any suitable manner, including, without limitation, by spinning the collected multi-potent cells at between about 60 and about 20,000 rpm for between about 10 seconds and about 120 minutes.
- the multi-potent cells can be centrifuged at any suitable sub-range or sub-ranges of the aforementioned ranges. Indeed, in some embodiments, the multi-potent cells are centrifuged at between about 1,000 and about 6,000 rpm for between about 4 minutes and about 30 minutes. In still other embodiments, the multi-potent cells are centrifuged at between about 2,800 and about 4,000 rpm for between about 10 and about 20 minutes.
- the concentrated multi-potent cells can be brought to any suitable concentration, in some embodiments, the concentrated multi-potent cells are between about 2 and about 30 times more concentrated than are such cells when they are initially obtained (including with any blood thinner used in the collection process). In some embodiments, the concentrated multi-potent cells can be concentrated to any suitable sub-range of the aforementioned concentration (including, without limitation, between about 5 and about 15 times as concentrated as the cells when they are originally collected). In one example, when 60 or 120 mls of bone marrow aspirate are drawn from one or more individuals, the bone marrow cells are concentrated down to a volume of about 6 ( ⁇ 2) mls and about 12 ( ⁇ 4) mls, respectively.
- the multi-potent cells e.g., bone marrow cells
- the cells are concentrated to between about 1 cell/ml and about 100 billion cells/ml (or any suitable sub-range thereof).
- the multi-potent cells are concentrated to between about 100 cells/ml and about 5 million cells/ml
- the multi-potent cells are concentrated to between about 1,000 cells/ml and about 1 million cells/ml.
- the multi-potent cells are concentrated at any concentration falling within any of the foregoing ranges.
- the multi-potent cells e.g., bone marrow cells
- the cells are separated from other materials (e.g., supernatant).
- the multi-potent cells and other material e.g., supernatant
- step 110 shows that, in some embodiments, the method includes obtaining plasma.
- the plasma can be collected form any suitable source, including, but not limited to, one or more autologous, allogenic, xenogeneic, and/or syngeneic cell sources). In some embodiments, however, the plasma is collected from the patient to whom the wound packing is to be applied.
- the plasma can be collected in any suitable manner, including, without limitation, by having blood drawn (e.g., with a syringe or other vessel comprising a blood thinner, such as heparin, anti-coagulate citrate dextrose (“ACDA”), and/or any other suitable material) from the patient and/or one or more other individuals, and then extracting plasma (e.g., platelet rich plasma (“PRP”), concentrated plasma, plasma, platelet concentrate, super concentrated plasma, growth factors, etc.) from the blood.
- plasma e.g., platelet rich plasma (“PRP”), concentrated plasma, plasma, platelet concentrate, super concentrated plasma, growth factors, etc.
- the plasma e.g., PRP, concentrated plasma, etc.
- the plasma e.g., PRP, concentrated plasma, etc.
- PRP concentrated plasma, etc.
- suitable methods for extracting plasma include, but are not limited to, the use of conventional plasma extraction kits (e.g., a plasma and serum preparation kit provided by Life Technologies of Grand Island N.Y., USA), a plasma concentration kit (e.g., a PLASMAX® and/or a PLASMAX® Plus plasma concentration system, produced by Biomet Biologics, LLC of Warsaw, Ind., USA); a Harvest PRP kit, produced by Harvest Technologies, Corp. of Beverly Mass., USA; etc.), centrifugation of whole blood and collecting the plasma supernatant, centrifugation of plasma supernatant to obtain platelet concentrate, and/or any other technique.
- a plasma concentration kit is used to obtain PRP and plasma that is relatively rich with growth factors (e.g., patient derived growth factors).
- plasma e.g., PRP
- the plasma can be collected from any suitable amount of blood.
- the plasma is extracted and/or concentrated from between about 10 and about 500 mls or more of blood.
- the plasma is concentrated from any suitable sub-range of the about 10 and about 500 mls of blood (e.g., between about 40 and about 80 mls).
- the plasma is extracted from between about 50 and about 56 mls of blood.
- the plasma can be concentrated to any suitable concentration, including, without limitation, to be between about 2 and about 30 times more concentrated than it was in the blood from which the plasma is obtained (including with any blood thinner and/or other materials used in the collection process). Moreover, in some embodiments, the plasma is concentrated to any suitable sub-range of the aforementioned concentration (including, without limitation, between about 5 and about 15 times as concentrated as the cells when they are originally collected). In one example, when about 55 mls of blood are combined with about 5 mls of blood thinner, about 6 mls ( ⁇ 2 mls) of PRP is produced).
- the plasma can be concentrated down to any suitable concentration, in some embodiments, the plasma is concentrated to between about 1 E ⁇ 10 g/ml and about 3 g/ml (or any suitable sub-range thereof). Indeed, while in some embodiments, the plasma is concentrated to between about 0.001 g/ml and about 2 g/ml, in some other embodiments, the plasma is concentrated to between about 0.1 g/ml and about 1 g/ml (or any subrange of the foregoing ranges.
- the plasma (e.g., PRP) can be collected and/or concentrated at any suitable time before being applied to the wound in the wound packing. In some embodiments, however, the blood is collected and/or concentrated within about 4 hours of the time in which the packing is applied to the wound (or any suitable subrange of such time period). In other embodiments, the plasma is concentrated within about an hour (e.g., between about 5 minutes and about 40 minutes) of the packing's application.
- step 115 shows that the multi-potent cells (e.g., bone marrow concentrate) and plasma (e.g., PRP, plasma concentrate, etc.) are combined.
- the multi-potent cells (concentrated bone marrow aspirate) and plasma (e.g., PRP) can be mixed together at any suitable ratio.
- the concentrated multi-potent cells e.g., bone marrow aspirate cells
- the plasma e.g., PRP and/or plasma concentrate
- the multi-potent cells and plasma are combined in any suitable sub-range of the aforementioned range (e.g., at a ratio of between about 1:1 and about 6:1).
- the bone marrow concentrate and PRP and/or plasma concentrate are mixed at a ratio between about 1.5:1 and about 4:1. In an example of such, about 5 cc of concentrated bone marrow aspirate are combined with about 3 cc of concentrated plasma.
- step 120 shows that, in some embodiments, the method 100 optionally includes adding the multi-potent cells and plasma to collagen and/or another suitable material.
- the multi-potent cells, plasma, and collagen can be mixed and/or otherwise combined with each other in any suitable manner.
- two or more of the components of the packing are mixed via pipetting, a mixer (e.g., a vortex mixer, etc.), a shaker (e.g., an orbital shaker, etc.), an ultrasonic bath or probe, diffusion, adsorption, the application of pressure to the collagen in a bath of one or more of the other described ingredients, and/or in any other suitable manner.
- the various components of the wound packing can be combined in any suitable order.
- the multi-potent cells e.g., concentrated bone marrow aspirate
- plasma e.g., PRP
- the multi-potent cells or the plasma is added to the collagen before the other of the two is.
- the multi-potent cells are placed in a vessel (e.g., a cup, bowl, mold, and/or other container that resembles (slightly or substantially) a shape of the wound), the collagen is added to the cells, and the plasma (e.g., PRP) is then added to the collagen and multi-potent cells.
- the multi-potent cells and plasma are mixed with the collagen simultaneously.
- the collagen is added to the multi-potent cells and/or the plasma.
- the collagen can comprise any collagen that is suitable for use in the wound packing.
- the collagen comprises a native collagen matrix, organized reconstituted collagen, reconstituted collagen, a collagen structure (e.g., native collagen) without an intact basement membrane, and/or a collagen structure with a fragmented basement membrane from one or more sheep, pigs, horses, humans, and/or other organisms.
- the collagen comprises one or more layers of a native collagen matrix (e.g., a collagen without a basement membrane or with a fractured basement membrane) taken from a sheep or human.
- the collagen comprises reconstituted collagen particulates, in some other embodiments, it comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or more layers of collagen matrix, depending on the depth of the wound to which the packing is to be applied.
- FIG. 2A shows an embodiment of the wound packing 150 that is configured for use in a relatively shallow wound and in which the wound packing 150 comprises a single layer of collagen 155 .
- FIG. 2B shows an embodiment in which the wound packing 150 comprises 4 layers of collagen 155 , for use in a relatively deep wound.
- FIGS. 2C and 2D respectively illustrate some embodiments in which the wound packing 150 comprises reconstituted collagen 156 and a collagen structure 158 .
- step 125 shows that, in some embodiments, the wound packing 150 is shaped such that it is able to fit in a wound, or, in some embodiments, to substantially correspond in shape to an interior shape of the wound. While the packing can be shaped in any suitable manner, in some embodiments, the collagen in the packing is cut, shaved, torn, ripped, trimmed, separated along perforated lines, packed, molded, layered, chamfered, and/or otherwise formed into any desired shape (e.g., a shape that resembles an interior shape of a wound).
- the other ingredients of the wound packing can be shaped in any suitable manner, including, without limitation, by being added a mold, a cup, and/or another container having a shape that resembles that of the wound, by being molded manually, and/or by being added to the collagen, with the collagen being shaped to fit the wound.
- step 130 shows that, in some embodiments, the wound packing 150 is gelled, thickened, and/or otherwise hardened.
- the wound packing e.g., multi-potent cells, plasma, and/or collagen
- the wound packing can be hardened in any suitable manner, including, without limitation, through the application of a thickening agent.
- suitable thickening agents include, but are not limited to, thrombin, recombinant thrombin, calcium chloride, and/or any other suitable ingredient or ingredients that are capable of causing the wound packing to gel and/or otherwise harden.
- thickening agent e.g., thrombin
- thickening agent is added to the multi-potent cells, plasma, and collagen a ratio of between about 1 E ⁇ 10 and about 1 E 10 (or any sub-range thereof) units of thrombin for every cc of the combination of multi-potent cells and plasma.
- thickening agent e.g., thrombin
- thickening agent is added to the multi-potent cells, plasma, and collagen at any suitable sub-range of the aforementioned range (e.g., between about 1 and about 20,000 (or between about 4,000 and about 6,000) units of thickening agent for every cc of the combination of multi-potent cells and plasma in the wound packing).
- thrombin e.g., thrombin
- calcium chloride is added to the multi-potent cells, plasma, and collagen a ratio of between 1 E ⁇ 10 and about 0.5 (or any sub-range thereof) moles of calcium chloride for every cc of the combination of multi-potent cells and plasma. In some other embodiments, calcium chloride is added to the multi-potent cells, plasma, and collagen at any suitable sub-range of the aforementioned range (e.g., between about 0.00001 and about 0.3 moles of thrombin for every cc of the combination of multi-potent cells and plasma in the wound packing).
- between about 4,000 and about 6,000 units of thrombin and between about 0.0001 moles and about 0.001 moles of calcium chloride are added to the wound packing for every cc of the combination of multi-potent cells and/or plasma in the packing.
- the thickening agent can be added to the wound packing 150 at any suitable time, including without limitation, by being added to the wound packing after the multi-potent cells and/or plasma are added to the collagen, by being added to the collagen before the multi-potent cells and/or plasma are added to the collagen, and/or at any other suitable time. In some embodiments, however, the thickening agent is added after the multi-potent cells and plasma have been dispersed in the collagen.
- an additional amount of thickening agent is added to the wound packing to help form a thicker barrier on one or more surfaces of the packing.
- any suitable additional amount of one or more thickening agents can be added to the packing. Indeed, in some embodiments, once the wound packing has initially been treated with thickening agent, between about 1 and about 20,000 units (or any sub-range thereof) of the thickening agent are added to an outer surface of the wound packing. In one example, after the wound packing has been hardened with an initial application of the thickening agent, between about 20 and about 7,000 units of thrombin (or a sub-range thereof) are applied to an outer surface of the packing.
- the described wound packing 150 can be used in any suitable manner.
- FIG. 3 shows that, in some embodiments, the method 300 for using the wound packing includes obtaining the packing (as shown at step 305 and as discussed above).
- Step 310 of FIG. 3 further shows that, in some embodiments, the method 300 includes obtaining skin fragments for application to the wound packing and/or wound.
- the skin fragments can be obtained from any suitable person, organism, and/or other source.
- the skin graft comprises an: autologous graft from the person who is to receive the wound packing, an isogenic graft from an identical twin of such recipient, an allogenic graft from another human, a xenogeneic graft from a non-human organism, and/or a synthetic material.
- the skin fragments are taken as an autograft (which may include, without limitation, cultured epithelial autografts) from the patient that will be receiving the wound packing.
- the skin fragments can also be obtained from any suitable portion of the donor's body.
- suitable locations for obtaining such grafts include, but are not limited to, a person's back, one or more of a donor's legs, arms, hands, buttocks, and/or other suitable locations.
- the skin grafts can be taken in any suitable manner, including, without limitation, through the use of a dermatome, expansion grafter, scalpel, razor blade, and/or another suitable instrument.
- the skin (e.g., epidermis and/or dermis) of the donor is grated, cut, chopped, micronized, and/or otherwise fragmented.
- the skin fragments can be made to be any suitable size, including, without limitation, to have an average diameter and/or width that is less than about 2 cm (or any sub-range thereof). Indeed, in some embodiments, the skin fragments have an average diameter and/or width of between about 0.0000001 mm and about 2 cm (or any subrange thereof). In still other embodiments, the skin fragments have an average diameter and/or width of between 0.001 mm and about 5 mm.
- step 315 shows that, in some embodiments, the described method 300 includes preparing a wound to receive the wound packing 150 .
- the wound can be prepared in any suitable manner that allows it to receive the wound packing, including, without limitation, by washing the wound, debriding the wound, disinfecting the wound, removing at least some necrotic tissue from the wound, causing the wound to bleed, applying an ointment to the wound, applying a disinfectant to the wound, and/or otherwise preparing the wound for healing.
- the wound is debrided or otherwise prepared such that it has a bleeding base, in some other embodiments, the wound packing is applied without such a base.
- FIG. 3 shows the wound packing 150 is placed in, placed on top of, and/or otherwise applied to the wound.
- the wound packing can be applied to the wound in any suitable manner, in some embodiments, the packing (e.g., the collagen matrix) is sewn, stapled, glued, taped, bandaged in place, and/or otherwise secured to the wound.
- FIG. 4 shows a representative embodiment in which the wound packing 150 is placed in a wound 160 and then held in place by a protective barrier 165 (as described below).
- step 325 shows that some embodiments of the method 300 include the application of skin seeds or fragments to the wound packing 150 .
- the skin seeds can be applied to any portion of the wound 160 and/or wound packing (e.g., on an external surface of the packing, between a portion of the packing and an interior surface of the wound, inside the wound packing, just below a surface of the wound packing, and/or in any other suitable location)
- FIG. 4 shows that, in accordance with at least some embodiments, the skin fragments 170 are applied to an external surface 175 of the wound packing 150 .
- skin fragments can, in some embodiments, help to epithelize the wound site, helping to close smaller wounds, helping larger wounds to approach a position in which they can be closed (e.g., via stitches, staples, bandages, another wound packing, etc.), and otherwise helping wounds to become more manageable.
- While the amount of skin fragments that are to be placed on the wound packing 150 and/or wound 160 can vary from one wound to another, depending on the size, severity, and condition of the various wounds, in some embodiments, between about 0.1 mg and about 2 grams (or any sub-range thereof) of skin fragments are applied per cm 2 of the external surface area of the wound packing that is exposed from the wound. Indeed, in some embodiments, between about 0.1 grams and about 1 gram of skin fragments per cm 2 of external surface of the wound packing that is exposed from the wound.
- step 330 shows that, in some embodiments, the method 300 optionally includes placing a protective barrier 165 over the wound packing 150 and wound 160 .
- a protective barrier 165 over the wound packing 150 and wound 160 .
- some non-limiting examples of such barriers include a single layer protective membrane, such as a layer of a-cellular dermis (e.g., a-cellular dermis from a human, pig, monkey, and/or any other suitable organism), a layer of a surgical silicone, and/or any other suitable single layer membrane; a bilayer protective membrane, such as a piece of an a-cellular dermis with a basement membrane, a piece of an a-cellular dermis comprising a layer of surgical silicone, and/or any other suitable bi-layer membrane; and/or any other suitable membrane comprising two or more layers.
- a single layer protective membrane such as a layer of a-cellular dermis (e.g., a-cellular dermis from a human, pig, monkey, and/or any
- the protective barrier can be attached to the wound 160 in any suitable manner, including, without limitation, via stitching, tape, staples, glue, a bandage, wrapping, and/or in any other suitable manner.
- FIG. 4 shows an embodiment in which the barrier 165 is attached to the wound 160 via a plurality of staples 180 .
- step 335 shows that, in some embodiments, the wound 160 and wound packing 150 is optionally dressed.
- the wound can be dressed in any suitable manner, including, without limitation, by being dressed with one or more bandages, pieces of gauze, wrappings, total contact casts, non-weight-bearing casts and/or dressings, wound veils, contact layer flex bandages, compressive dressings, KERLIXTM wrappings, absorbent abdominal pads, calcium alginate applications, hydra fibers, fenestrated gauze drain sponges, TRIACTTM treatments (e.g., produced by Hollister of Libertyville, Ill., USA), ointments, petroleum-based jellies, and/or with any other suitable type of wound dressings.
- TRIACTTM treatments e.g., produced by Hollister of Libertyville, Ill., USA
- step 340 shows that the wound 160 can be checked periodically, and that if the wound is healed in a desired period of time, one or more portions of the method 300 can be repeated. Indeed, in some embodiments, if a wound has not completely healed in a desired period of time (e.g., between about 3 days and about 2 months, or any sub-range thereof), another wound packing (e.g., a smaller wound packing where the wound has partially healed) can be added to the wound.
- a desired period of time e.g., between about 3 days and about 2 months, or any sub-range thereof
- another wound packing e.g., a smaller wound packing where the wound has partially healed
- the described systems and methods can be modified in any suitable manner that allows the described wound packing 150 to be used to treat a wound 160 .
- a modification in order to provide vascular stimulation that can further allow the wound to heal, multi-potent cells and/or plasma are injected into the individual around the wound.
- the wound packing comprise multi-potent cells, plasma, and a thickening agent, but lacks collagen.
- some embodiments of the wound packing comprise plasma, collagen, and a thickening agent but lack multi-potent cells.
- some embodiments of the wound packing comprise multi-potent cells, collagen, and a thickening agent, but lack plasma.
- the present invention relates to wound care.
- some implementations of the present invention relate to systems and methods for treating a wound.
- some implementations of the present invention relate to methods for forming a wound packing comprising multi-potent cells (e.g., bone marrow cells), plasma, collagen, and/or a thickening agent.
- multi-potent cells e.g., bone marrow cells
- plasma e.g., collagen
- collagen e.g., collagen
- a thickening agent e.g., collagen, collagen, and/or a thickening agent.
- skin seeds are optionally applied to a surface of the packing and a protective barrier is applied over the packing.
- one object e.g., a material, element, structure, member, etc.
- one object can be on, disposed on, attached to, connected to, or coupled to another object—regardless of whether the one object is directly on, attached, connected, or coupled to the other object, or whether there are one or more intervening objects between the one object and the other object.
- directions e.g., on top of, below, above, top, bottom, side, up, down, under, over, upper, lower, lateral, medial, vertical, horizontal, distal, proximal, etc.
- directions are relative and provided solely by way of example and for ease of illustration and discussion and not by way of limitation.
- elements e.g., elements a, b, c
- such reference is intended to include any one of the listed elements by itself, any combination of less than all of the listed elements, and/or a combination of all of the listed elements.
- the terms a, an, and one may each be interchangeable with the terms at least one and one or more.
- step is used herein, that term may be used to simply draw attention to different portions of the described methods and is not meant to delineate a starting point or a stopping point, or order for any portion of the methods, or to be limiting in any other way.
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 15/620,531 (Attorney Docket No. 28973.4), filed Jun. 12, 2017, and entitled “SYSTEMS AND METHODS FOR TREATING A WOUND WITH WOUND PACKING,” which claims priority to U.S. Provisional Patent Application Ser. No. 62/348,698 (Attorney Docket No. 22996.3), filed Jun. 10, 2016, and entitled “SYSTEMS AND METHODS FOR TREATING A WOUND WITH A WOUND PACKING;” each of which is incorporated herein by reference in its entirety.
- The present invention relates to systems and methods for treating a wound. In particular, some implementations of the present invention relate to methods for forming a wound packing comprising multi-potent cells (e.g., bone marrow cells), plasma, collagen, and/or a thickening agent. In some further implementations, once the wound packing is applied to a wound, skin seeds are optionally applied to a surface of the packing and a protective barrier is applied over the packing.
- Many people across the world suffer from skin ulcerations and injuries. For instance, many people who suffer from diabetes, who are bedridden, or who are confined to a wheelchair can also suffer from poor blood flow in some portions of their bodies, such as their appendages. As a result, such people can be at a relatively high risk of developing sores, ulcers, and other wounds on their body. While these wounds can form on virtually any portion of a person's body, some people develop particularly chronic sores, ulcers, and/or other wounds on their legs and feet—especially on the soles of their feet.
- In any case, chronic sores, ulcers, and other wounds can dramatically affect an individual's life, limiting the individual's ability to move (e.g., walk), work, and play. Moreover, such wounds can cause pain and take an emotional toll on the individual, costing the individual and/or others relatively large amounts of money, energy, and time spent in, and for, recovery. Additionally, in some extreme cases, such sores, ulcers, and other wounds can lead to amputation, which can dramatically complicate life, be physically and emotionally draining, increase healthcare costs, and otherwise be extremely undesirable.
- While a variety of treatments, ointments, bandages, medical procedures, and other systems and methods have been used to treat chronic wounds, such systems and methods are not necessary without their shortcomings. Indeed, some methods and treatments for caring for persistent wounds may be relatively ineffective at treating chronic wounds. As a result, some systems and methods for treating such wounds may never actually result in the wound closing and healing. In some other cases, while some conventional systems and methods may help a chronic wound to heal, some such systems and methods can be relatively slow—drawing out treatment and recovery time over a relatively long period of time.
- Thus, while techniques currently exist that are used to treat chronic ulcerations, sores, and other wounds, challenges still exist, including those mentioned above. Accordingly, it would be an improvement in the art to augment or even replace current techniques with other techniques.
- The present invention relates to systems and methods for treating a wound. In particular, some implementations of the present invention relate to methods for forming a wound packing comprising multi-potent cells (e.g., bone marrow cells), plasma, collagen, and/or a thickening agent. In some further implementations, once the wound packing is applied to a wound, skin seeds are optionally applied to a surface of the packing and a protective barrier is applied over the packing.
- While the described methods can comprise any suitable step or characteristic, in some implementations, the described methods include combining multi-potent cells (e.g., cells from bone marrow, amniotic tissue, amniotic fluid, placental tissue, fat tissue, umbilical cord tissue, stem cells, and/or any other suitable source) with plasma (e.g., platelet rich plasma, concentrated plasma, super concentrated plasma, plasma, and/or any other suitable type of plasma), and collagen (e.g., native collagen, organized reconstituted collagen, collagen, and/or any other suitable type of collagen). In some implementations, the various components are formed into a shape that substantially corresponds to the shape of a wound. Additionally, in some implementations, thrombin, calcium chloride, one or more serine proteases, and/or any other suitable thickening agent or agents are combined with the multi-potent cells, plasma, and/or collagen to coagulate, gel, and/or otherwise harden the components to form a wound packing.
- In some implementations, the wound packing is inserted into or otherwise applied to a wound (e.g., a wound that has been cleaned, debrided, disinfected, had necrotic tissue removed, that is bleeding, and/or that is otherwise ready to receive the packing). Moreover, in some such implementations, “skin seeds” or skin graft fragments (e.g., micronized and/or otherwise fragmented epidermal and/or dermal tissue) are applied to the wound packing (e.g., an outer surface of the wound packing). Additionally, in some cases, the wound, wound packing, and skin cells are covered with a protective barrier. In this regard, some non-limiting examples of such barriers include a single layer protective membrane, such as a layer of a-cellular dermis (e.g., human a-cellular dermis, animal dermis, etc.), a layer of silicon (e.g., one or more layers of a surgical silicone), and/or any other suitable single layer membrane; a bilayer protective membrane, such as a piece of an a-cellular dermis with a basement membrane, a piece of an a-cellular dermis comprising a layer of surgical silicone, and/or any other suitable bi-layer membrane; and/or any other suitable membrane comprising two or more layers.
- In some implementations, once the wound packing has been placed in and/or on a wound, the wound is dressed further. While the wound can be dressed in any suitable manner, in some cases, the wound is dressed with: gauze, a bandage, a wrap, a total contact cast, a non-weight-bearing cast or dressing, a wound veil, a contact layer flex bandage, a compressive dressing, KERLIX™ wrapping, an absorbent abdominal pad, calcium alginate, a hydra fiber, a fenestrated gauze drain sponge, a TRIACT™ treatment (e.g., produced by Hollister of Libertyville, Ill., USA), an ointment, a petroleum-based jelly, and/or with any other suitable type of wound dressing.
- As mentioned, the described systems and methods can be modified in any suitable manner. Indeed, in some implementations, the wound packing lacks multi-potent cells, while still comprising plasma and collagen. In some other implementations, the wound packing lacks collagen. In still other non-limiting implementations, the wound packing is used without the application of skin seeds to an external surface of the packing. In still other implementations, one or more components of the wound packing (e.g., the multi-potent cells, the plasma, skin seeds, etc.) are autologous to the person to which the wound packing is to be applied. In yet other implementations, however, one or more components of the wound packing are autologous, allogeneic, xenogeneic, and/or syngeneic to the person to which the wound packing is to be applied.
- While the described systems and methods may be particularly useful in the area of treating one or more sores, ulcerations, and/or other wounds on the sole (and other portions) of an individual's foot, those skilled in the art can appreciate that the described systems and methods can be used in a variety of different applications and in a variety of different areas of manufacture to treat a wide range of injuries, in any suitable location, including, without limitation, injuries to an individual's arm, hand, finger, toe, leg, thigh, calf, buttocks, back, torso, abdomen, neck, head, face, etc.). Indeed, in some implementations, the described systems and methods are used to treat surgical wounds, bed sores, pressure ulcers, wound dehiscence, graft donor sites, lesions, sores, vascular ulcers, diabetic ulcers (including, without limitation, diabetic foot ulcers), trauma wounds, tears, tunneling wounds, abrasions, sores, lacerations, and/or other wounds.
- These and other features and advantages of the present invention will be set forth or will become more fully apparent in the description that follows. Furthermore, the features and advantages of the invention may be learned by the practice of the invention or will be obvious from the description, as set forth hereinafter.
- In order that the manner in the above-recited and other features and advantages of the present invention are obtained, a more particular description of the invention will be rendered by reference to specific embodiments thereof, which are illustrated in the appended drawings. Understanding that the drawings depict only typical embodiments of the present invention and are not, therefore, to be considered as limiting the scope of the invention, the present invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
-
FIG. 1 illustrates a flowchart depicting a method for forming a wound packing in accordance with a representative embodiment; -
FIGS. 2A-2D each illustrate a cross-sectional view of a different representative embodiment of the wound packing; -
FIG. 3 illustrates a flowchart depicting a method for treating a wound with the wound packing in accordance with a representative embodiment; and -
FIG. 4 illustrates a cross-sectional view of the wound packing applied to a wound in accordance with a representative embodiment. - The present invention relates to systems and methods for treating a wound. In particular, some implementations of the present invention relate to methods for forming a wound packing comprising multi-potent cells (e.g., bone marrow cells), plasma, collagen, and/or a thickening agent. In some further implementations, once the wound packing is applied to a wound, skin seeds are optionally applied to a surface of the packing and a protective barrier is applied over the packing.
- In accordance with some embodiments, the described wound packing and its associated methods are configured to help wounds (including chronic wounds) close up and otherwise heal. While the wound packing can be formed in any suitable manner,
FIG. 1 illustrates a representative embodiment of amethod 100 for forming the described wound packing. While such method 100 (and all other methods describe herein) can be modified in any suitable manner (e.g., with any suitable portion of the method being omitted, added to, reordered, performed simultaneously with another portion of the method, performed independently, substituted with another technique, and/or otherwise being modified in any suitable manner),step 105 inFIG. 1 shows that, in some embodiments, themethod 100 includes obtaining multi-potent cells. - Where the wound packing comprises multi-potent cells, the multi-potent cells can comprise any suitable cells that are capable of differentiating and helping a wound to which they are applied to heal. In this regard, the term multi-potent cells may be used herein to refer to cells that are totipotent, pluripotent, and/or multipotent. Some non-limiting examples of such cells include bone marrow cells, mesenchymal cells, stem cells, neural stem cells, cells from amniotic fluid, placental cells, amniotic membrane cells, and/or any other suitable unspecialized (e.g., multi-potent and/or undifferentiated) cells that can differentiate into specialized cells with specific functions that are useful in the wound packing.
- The multi-potent cells can be obtained from any suitable organism, including, without limitation, from the patient to whom the wound packing is to be applied (e.g., autologous cells), from one or more third-party individuals (e.g., allogenic cells), from an identical twin (e.g., syngeneic cells), from an animal of a different species (e.g., xenogeneic cells), etc. In some embodiments, however, the multi-potent cells comprise autologous cells taken from the patient. As used herein, the terms patient and individual (and variations thereof) may be used to refer to any person or other subject to whom the described wound packing can be applied.
- The multi-potent cells can be obtained from any suitable source, including, without limitation, from bone marrow (including, without limitation, mesenchymal cells), placental tissue, amniotic fluid, amniotic membrane tissue, umbilical cord tissue, brain tissues, blood vessels, skeletal muscle, skin, teeth, heart tissue, liver tissue, gut tissue, etc. Moreover, the multi-potent cells can be obtained from any suitable location. Indeed, in some embodiments in which the multi-potent cells comprise bone marrow cells, the bone marrow cells are collected from one or more iliac crests, calcanei, sternums, lumbar vertebrae, femurs, tibias, and/or other suitable locations, from one or more individuals.
- The multi-potent cells can be obtained in any suitable manner, including, without limitation, via aspiration (e.g., with a bone marrow aspirate needle or otherwise), biopsy (e.g., trephine biopsy or otherwise), excision, and/or in any other suitable manner. Indeed, in some embodiments, the multi-potent cells comprise bone marrow aspirate taken from the iliac crest, calcaneus, sternum, and/or tibia of the patient to whom the wound packing is to be applied. In such embodiments, the cells can be aspirated in any suitable manner, including, without limitation, via a bone marrow aspirate needle and syringe coated with a blood thinner (e.g., heparin, anti-coagulate citrate dextrose, and/or any other suitable thinner).
- In order to form the wound packing, any suitable amount of material comprising multi-potent cells can be extracted from an organism (e.g., the patient). Indeed, in some embodiments in which the multi-potent cells comprise bone marrow cells, between about 1 and about 300 mls of bone marrow aspirate are initially collected. In other embodiments, any suitable amount of multi-potent cells (e.g., bone marrow aspirate) that falls in a sub-range (e.g., between about 40 mls and about 200 mls) of the aforementioned range can be extracted for use in formation in
- In some embodiments, the multi-potent cells are optionally concentrated for inclusion in the wound packing. In this regard, the multi-potent cells (e.g., bone marrow cells) can be concentrated in any suitable manner, including, without limitation, via a conventional or novel cell concentration kit (e.g., a BIOCUE™ kit, produced by Biomet Biologics, LLC of Warsaw, Ind., USA) centrifugation, filtration, separation, and/or any other conventional or novel technique that is suitable for concentrating cells for use in the wound packing.
- In some embodiments, the multi-potent cells are concentrated through centrifugation. In such embodiments, the centrifugation can be performed in any suitable manner, including, without limitation, by spinning the collected multi-potent cells at between about 60 and about 20,000 rpm for between about 10 seconds and about 120 minutes. Moreover, the multi-potent cells can be centrifuged at any suitable sub-range or sub-ranges of the aforementioned ranges. Indeed, in some embodiments, the multi-potent cells are centrifuged at between about 1,000 and about 6,000 rpm for between about 4 minutes and about 30 minutes. In still other embodiments, the multi-potent cells are centrifuged at between about 2,800 and about 4,000 rpm for between about 10 and about 20 minutes.
- While the multi-potent cells can be brought to any suitable concentration, in some embodiments, the concentrated multi-potent cells are between about 2 and about 30 times more concentrated than are such cells when they are initially obtained (including with any blood thinner used in the collection process). In some embodiments, the concentrated multi-potent cells can be concentrated to any suitable sub-range of the aforementioned concentration (including, without limitation, between about 5 and about 15 times as concentrated as the cells when they are originally collected). In one example, when 60 or 120 mls of bone marrow aspirate are drawn from one or more individuals, the bone marrow cells are concentrated down to a volume of about 6 (±2) mls and about 12 (±4) mls, respectively. Said differently, while the multi-potent cells (e.g., bone marrow cells) can be concentrated down to any suitable concentration, in some embodiments, the cells are concentrated to between about 1 cell/ml and about 100 billion cells/ml (or any suitable sub-range thereof). Indeed, while in some embodiments, the multi-potent cells are concentrated to between about 100 cells/ml and about 5 million cells/ml, in some other embodiments, the multi-potent cells are concentrated to between about 1,000 cells/ml and about 1 million cells/ml. In still other embodiments, the multi-potent cells are concentrated at any concentration falling within any of the foregoing ranges.
- In some embodiments, once the multi-potent cells (e.g., bone marrow cells) have been concentrated (e.g., via centrifugation), the cells are separated from other materials (e.g., supernatant). In this regard, the multi-potent cells and other material (e.g., supernatant) can be separated from each other in any suitable manner, including, but not limited to, decantation, vacuuming, and/or any other suitable method.
- Continuing with the
method 100, step 110 shows that, in some embodiments, the method includes obtaining plasma. In this regard, the plasma can be collected form any suitable source, including, but not limited to, one or more autologous, allogenic, xenogeneic, and/or syngeneic cell sources). In some embodiments, however, the plasma is collected from the patient to whom the wound packing is to be applied. - The plasma can be collected in any suitable manner, including, without limitation, by having blood drawn (e.g., with a syringe or other vessel comprising a blood thinner, such as heparin, anti-coagulate citrate dextrose (“ACDA”), and/or any other suitable material) from the patient and/or one or more other individuals, and then extracting plasma (e.g., platelet rich plasma (“PRP”), concentrated plasma, plasma, platelet concentrate, super concentrated plasma, growth factors, etc.) from the blood. In this regard, the plasma (e.g., PRP, concentrated plasma, etc.) can be extracted from collected blood in any suitable manner. Some examples of suitable methods for extracting plasma include, but are not limited to, the use of conventional plasma extraction kits (e.g., a plasma and serum preparation kit provided by Life Technologies of Grand Island N.Y., USA), a plasma concentration kit (e.g., a PLASMAX® and/or a PLASMAX® Plus plasma concentration system, produced by Biomet Biologics, LLC of Warsaw, Ind., USA); a Harvest PRP kit, produced by Harvest Technologies, Corp. of Plymouth Mass., USA; etc.), centrifugation of whole blood and collecting the plasma supernatant, centrifugation of plasma supernatant to obtain platelet concentrate, and/or any other technique. In some embodiments, however, a plasma concentration kit is used to obtain PRP and plasma that is relatively rich with growth factors (e.g., patient derived growth factors).
- In order to prepare the wound packing, plasma (e.g., PRP) can be collected from any suitable amount of blood. In some embodiments, however, the plasma is extracted and/or concentrated from between about 10 and about 500 mls or more of blood. In other embodiments, the plasma is concentrated from any suitable sub-range of the about 10 and about 500 mls of blood (e.g., between about 40 and about 80 mls). Indeed, in some embodiments, the plasma is extracted from between about 50 and about 56 mls of blood.
- The plasma can be concentrated to any suitable concentration, including, without limitation, to be between about 2 and about 30 times more concentrated than it was in the blood from which the plasma is obtained (including with any blood thinner and/or other materials used in the collection process). Moreover, in some embodiments, the plasma is concentrated to any suitable sub-range of the aforementioned concentration (including, without limitation, between about 5 and about 15 times as concentrated as the cells when they are originally collected). In one example, when about 55 mls of blood are combined with about 5 mls of blood thinner, about 6 mls (±2 mls) of PRP is produced). Said differently, while the plasma can be concentrated down to any suitable concentration, in some embodiments, the plasma is concentrated to between about 1E −10 g/ml and about 3 g/ml (or any suitable sub-range thereof). Indeed, while in some embodiments, the plasma is concentrated to between about 0.001 g/ml and about 2 g/ml, in some other embodiments, the plasma is concentrated to between about 0.1 g/ml and about 1 g/ml (or any subrange of the foregoing ranges.
- The plasma (e.g., PRP) can be collected and/or concentrated at any suitable time before being applied to the wound in the wound packing. In some embodiments, however, the blood is collected and/or concentrated within about 4 hours of the time in which the packing is applied to the wound (or any suitable subrange of such time period). In other embodiments, the plasma is concentrated within about an hour (e.g., between about 5 minutes and about 40 minutes) of the packing's application.
- Continuing with the method, step 115 shows that the multi-potent cells (e.g., bone marrow concentrate) and plasma (e.g., PRP, plasma concentrate, etc.) are combined. In this regard, the multi-potent cells (concentrated bone marrow aspirate) and plasma (e.g., PRP) can be mixed together at any suitable ratio. Indeed in some embodiments, the concentrated multi-potent cells (e.g., bone marrow aspirate cells) are combined with the plasma (e.g., PRP and/or plasma concentrate) at a ratio between about 100:1 and about 1:100, by volume. In other embodiments, the multi-potent cells and plasma are combined in any suitable sub-range of the aforementioned range (e.g., at a ratio of between about 1:1 and about 6:1). Indeed, in some embodiments, the bone marrow concentrate and PRP and/or plasma concentrate are mixed at a ratio between about 1.5:1 and about 4:1. In an example of such, about 5 cc of concentrated bone marrow aspirate are combined with about 3 cc of concentrated plasma.
- Continuing with
FIG. 1 , step 120 shows that, in some embodiments, themethod 100 optionally includes adding the multi-potent cells and plasma to collagen and/or another suitable material. In this regard, the multi-potent cells, plasma, and collagen can be mixed and/or otherwise combined with each other in any suitable manner. In some embodiments, two or more of the components of the packing are mixed via pipetting, a mixer (e.g., a vortex mixer, etc.), a shaker (e.g., an orbital shaker, etc.), an ultrasonic bath or probe, diffusion, adsorption, the application of pressure to the collagen in a bath of one or more of the other described ingredients, and/or in any other suitable manner. - The various components of the wound packing can be combined in any suitable order. Indeed, in some embodiments, the multi-potent cells (e.g., concentrated bone marrow aspirate) and plasma (e.g., PRP) are mixed together before being added to the collagen. In some other embodiments, either the multi-potent cells or the plasma is added to the collagen before the other of the two is. In one such example, the multi-potent cells are placed in a vessel (e.g., a cup, bowl, mold, and/or other container that resembles (slightly or substantially) a shape of the wound), the collagen is added to the cells, and the plasma (e.g., PRP) is then added to the collagen and multi-potent cells. In still other embodiments, the multi-potent cells and plasma are mixed with the collagen simultaneously. In still other embodiments, the collagen is added to the multi-potent cells and/or the plasma.
- With respect to the collagen, the collagen can comprise any collagen that is suitable for use in the wound packing. In some embodiments, the collagen comprises a native collagen matrix, organized reconstituted collagen, reconstituted collagen, a collagen structure (e.g., native collagen) without an intact basement membrane, and/or a collagen structure with a fragmented basement membrane from one or more sheep, pigs, horses, humans, and/or other organisms. Indeed, in some embodiments, the collagen comprises one or more layers of a native collagen matrix (e.g., a collagen without a basement membrane or with a fractured basement membrane) taken from a sheep or human.
- Although, in some embodiments, the collagen comprises reconstituted collagen particulates, in some other embodiments, it comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or more layers of collagen matrix, depending on the depth of the wound to which the packing is to be applied. By way of non-limiting illustration,
FIG. 2A shows an embodiment of the wound packing 150 that is configured for use in a relatively shallow wound and in which the wound packing 150 comprises a single layer ofcollagen 155. In contrast,FIG. 2B shows an embodiment in which the wound packing 150 comprises 4 layers ofcollagen 155, for use in a relatively deep wound. Additionally,FIGS. 2C and 2D respectively illustrate some embodiments in which the wound packing 150 comprises reconstitutedcollagen 156 and acollagen structure 158. - Returning to
FIG. 1 , step 125 shows that, in some embodiments, the wound packing 150 is shaped such that it is able to fit in a wound, or, in some embodiments, to substantially correspond in shape to an interior shape of the wound. While the packing can be shaped in any suitable manner, in some embodiments, the collagen in the packing is cut, shaved, torn, ripped, trimmed, separated along perforated lines, packed, molded, layered, chamfered, and/or otherwise formed into any desired shape (e.g., a shape that resembles an interior shape of a wound). Similarly, the other ingredients of the wound packing can be shaped in any suitable manner, including, without limitation, by being added a mold, a cup, and/or another container having a shape that resembles that of the wound, by being molded manually, and/or by being added to the collagen, with the collagen being shaped to fit the wound. - Continuing with
FIG. 1 , step 130 shows that, in some embodiments, the wound packing 150 is gelled, thickened, and/or otherwise hardened. In this regard, the wound packing (e.g., multi-potent cells, plasma, and/or collagen) can be hardened in any suitable manner, including, without limitation, through the application of a thickening agent. Some examples of suitable thickening agents include, but are not limited to, thrombin, recombinant thrombin, calcium chloride, and/or any other suitable ingredient or ingredients that are capable of causing the wound packing to gel and/or otherwise harden. - Where a thickening agent is added to the wound packing 150, any suitable amount of the thickening agent can be added. Indeed, in some embodiments, thickening agent (e.g., thrombin) is added to the multi-potent cells, plasma, and collagen a ratio of between about 1E −10 and about 1E 10 (or any sub-range thereof) units of thrombin for every cc of the combination of multi-potent cells and plasma. In some other embodiments, thickening agent (e.g., thrombin) is added to the multi-potent cells, plasma, and collagen at any suitable sub-range of the aforementioned range (e.g., between about 1 and about 20,000 (or between about 4,000 and about 6,000) units of thickening agent for every cc of the combination of multi-potent cells and plasma in the wound packing). Indeed, in some embodiments, between about 100 and about 6,500 units of thrombin are added for every cc of the combination of multi-potent cells and plasma in the wound packing.
- In some other embodiments, calcium chloride is added to the multi-potent cells, plasma, and collagen a ratio of between 1E −10 and about 0.5 (or any sub-range thereof) moles of calcium chloride for every cc of the combination of multi-potent cells and plasma. In some other embodiments, calcium chloride is added to the multi-potent cells, plasma, and collagen at any suitable sub-range of the aforementioned range (e.g., between about 0.00001 and about 0.3 moles of thrombin for every cc of the combination of multi-potent cells and plasma in the wound packing). In one example, between about 4,000 and about 6,000 units of thrombin and between about 0.0001 moles and about 0.001 moles of calcium chloride are added to the wound packing for every cc of the combination of multi-potent cells and/or plasma in the packing.
- The thickening agent can be added to the wound packing 150 at any suitable time, including without limitation, by being added to the wound packing after the multi-potent cells and/or plasma are added to the collagen, by being added to the collagen before the multi-potent cells and/or plasma are added to the collagen, and/or at any other suitable time. In some embodiments, however, the thickening agent is added after the multi-potent cells and plasma have been dispersed in the collagen.
- In some embodiments, after the thickening agent (e.g., thrombin) has caused the wound packing to coagulate or otherwise harden, and/or after the wound packing (prior to and/or after application of an initial dose of thickening agent) is placed in the wound, an additional amount of thickening agent is added to the wound packing to help form a thicker barrier on one or more surfaces of the packing. In this regard, any suitable additional amount of one or more thickening agents can be added to the packing. Indeed, in some embodiments, once the wound packing has initially been treated with thickening agent, between about 1 and about 20,000 units (or any sub-range thereof) of the thickening agent are added to an outer surface of the wound packing. In one example, after the wound packing has been hardened with an initial application of the thickening agent, between about 20 and about 7,000 units of thrombin (or a sub-range thereof) are applied to an outer surface of the packing.
- The described wound packing 150 can be used in any suitable manner. In one non-limiting example,
FIG. 3 shows that, in some embodiments, themethod 300 for using the wound packing includes obtaining the packing (as shown atstep 305 and as discussed above). Step 310 ofFIG. 3 further shows that, in some embodiments, themethod 300 includes obtaining skin fragments for application to the wound packing and/or wound. In this regard, the skin fragments can be obtained from any suitable person, organism, and/or other source. Indeed, in some embodiments, the skin graft comprises an: autologous graft from the person who is to receive the wound packing, an isogenic graft from an identical twin of such recipient, an allogenic graft from another human, a xenogeneic graft from a non-human organism, and/or a synthetic material. In some embodiments, however, the skin fragments are taken as an autograft (which may include, without limitation, cultured epithelial autografts) from the patient that will be receiving the wound packing. - The skin fragments can also be obtained from any suitable portion of the donor's body. Some examples of suitable locations for obtaining such grafts include, but are not limited to, a person's back, one or more of a donor's legs, arms, hands, buttocks, and/or other suitable locations. Additionally, the skin grafts can be taken in any suitable manner, including, without limitation, through the use of a dermatome, expansion grafter, scalpel, razor blade, and/or another suitable instrument.
- In some embodiments, the skin (e.g., epidermis and/or dermis) of the donor is grated, cut, chopped, micronized, and/or otherwise fragmented. In this regard, the skin fragments can be made to be any suitable size, including, without limitation, to have an average diameter and/or width that is less than about 2 cm (or any sub-range thereof). Indeed, in some embodiments, the skin fragments have an average diameter and/or width of between about 0.0000001 mm and about 2 cm (or any subrange thereof). In still other embodiments, the skin fragments have an average diameter and/or width of between 0.001 mm and about 5 mm.
- Continuing with
FIG. 3 , step 315 shows that, in some embodiments, the describedmethod 300 includes preparing a wound to receive the wound packing 150. In this regard, the wound can be prepared in any suitable manner that allows it to receive the wound packing, including, without limitation, by washing the wound, debriding the wound, disinfecting the wound, removing at least some necrotic tissue from the wound, causing the wound to bleed, applying an ointment to the wound, applying a disinfectant to the wound, and/or otherwise preparing the wound for healing. Although in some embodiments, the wound is debrided or otherwise prepared such that it has a bleeding base, in some other embodiments, the wound packing is applied without such a base. - At
step 320,FIG. 3 shows the wound packing 150 is placed in, placed on top of, and/or otherwise applied to the wound. While the wound packing can be applied to the wound in any suitable manner, in some embodiments, the packing (e.g., the collagen matrix) is sewn, stapled, glued, taped, bandaged in place, and/or otherwise secured to the wound. By way of non-limiting illustration,FIG. 4 shows a representative embodiment in which the wound packing 150 is placed in awound 160 and then held in place by a protective barrier 165 (as described below). - Returning to
FIG. 3 , step 325 shows that some embodiments of themethod 300 include the application of skin seeds or fragments to the wound packing 150. While the skin seeds can be applied to any portion of thewound 160 and/or wound packing (e.g., on an external surface of the packing, between a portion of the packing and an interior surface of the wound, inside the wound packing, just below a surface of the wound packing, and/or in any other suitable location),FIG. 4 shows that, in accordance with at least some embodiments, the skin fragments 170 are applied to anexternal surface 175 of the wound packing 150. In this example, skin fragments can, in some embodiments, help to epithelize the wound site, helping to close smaller wounds, helping larger wounds to approach a position in which they can be closed (e.g., via stitches, staples, bandages, another wound packing, etc.), and otherwise helping wounds to become more manageable. - While the amount of skin fragments that are to be placed on the wound packing 150 and/or wound 160 can vary from one wound to another, depending on the size, severity, and condition of the various wounds, in some embodiments, between about 0.1 mg and about 2 grams (or any sub-range thereof) of skin fragments are applied per cm2 of the external surface area of the wound packing that is exposed from the wound. Indeed, in some embodiments, between about 0.1 grams and about 1 gram of skin fragments per cm2 of external surface of the wound packing that is exposed from the wound.
- Returning again to
FIG. 3 , step 330 shows that, in some embodiments, themethod 300 optionally includes placing aprotective barrier 165 over the wound packing 150 and wound 160. In this regard, some non-limiting examples of such barriers include a single layer protective membrane, such as a layer of a-cellular dermis (e.g., a-cellular dermis from a human, pig, monkey, and/or any other suitable organism), a layer of a surgical silicone, and/or any other suitable single layer membrane; a bilayer protective membrane, such as a piece of an a-cellular dermis with a basement membrane, a piece of an a-cellular dermis comprising a layer of surgical silicone, and/or any other suitable bi-layer membrane; and/or any other suitable membrane comprising two or more layers. - Where the wound packing 150 is covered with a
protective barrier 165, the protective barrier can be attached to thewound 160 in any suitable manner, including, without limitation, via stitching, tape, staples, glue, a bandage, wrapping, and/or in any other suitable manner. By way of non-limiting illustration,FIG. 4 shows an embodiment in which thebarrier 165 is attached to thewound 160 via a plurality ofstaples 180. - Returning again to
FIG. 3 , step 335 shows that, in some embodiments, thewound 160 and wound packing 150 is optionally dressed. In this regard, the wound can be dressed in any suitable manner, including, without limitation, by being dressed with one or more bandages, pieces of gauze, wrappings, total contact casts, non-weight-bearing casts and/or dressings, wound veils, contact layer flex bandages, compressive dressings, KERLIX™ wrappings, absorbent abdominal pads, calcium alginate applications, hydra fibers, fenestrated gauze drain sponges, TRIACT™ treatments (e.g., produced by Hollister of Libertyville, Ill., USA), ointments, petroleum-based jellies, and/or with any other suitable type of wound dressings. - Continuing with
FIG. 3 , step 340 shows that thewound 160 can be checked periodically, and that if the wound is healed in a desired period of time, one or more portions of themethod 300 can be repeated. Indeed, in some embodiments, if a wound has not completely healed in a desired period of time (e.g., between about 3 days and about 2 months, or any sub-range thereof), another wound packing (e.g., a smaller wound packing where the wound has partially healed) can be added to the wound. - As previously mentioned, the described systems and methods can be modified in any suitable manner that allows the described wound packing 150 to be used to treat a
wound 160. Indeed, in one example of a modification, in order to provide vascular stimulation that can further allow the wound to heal, multi-potent cells and/or plasma are injected into the individual around the wound. - In another example of a suitable modification, in some embodiments, the wound packing comprise multi-potent cells, plasma, and a thickening agent, but lacks collagen. In still another example of a suitable modification, some embodiments of the wound packing comprise plasma, collagen, and a thickening agent but lack multi-potent cells. In yet another example of a modification, some embodiments of the wound packing comprise multi-potent cells, collagen, and a thickening agent, but lack plasma.
- Thus, the present invention relates to wound care. In particular, some implementations of the present invention relate to systems and methods for treating a wound. In particular, some implementations of the present invention relate to methods for forming a wound packing comprising multi-potent cells (e.g., bone marrow cells), plasma, collagen, and/or a thickening agent. In some further implementations, once the wound packing is applied to a wound, skin seeds are optionally applied to a surface of the packing and a protective barrier is applied over the packing.
- In addition to any previously indicated modification, numerous other variations and alternative arrangements may be devised by those skilled in the art without departing from the spirit and scope of this description, and appended claims are intended to cover such modifications and arrangements. Thus, while the information has been described above with particularity and detail in connection with what is presently deemed to be the most practical and preferred aspects, it will be apparent to those of ordinary skill in the art that numerous modifications, including, but not limited to, form, function, manner of operation, and use may be made without departing from the principles and concepts set forth herein. Also, as used herein, the examples, implementations, and embodiments, in all respects, are meant to be illustrative only and should not be construed to be limiting in any manner. In addition, as the terms on, disposed on, attached to, connected to, coupled to, etc. are used herein, one object (e.g., a material, element, structure, member, etc.) can be on, disposed on, attached to, connected to, or coupled to another object—regardless of whether the one object is directly on, attached, connected, or coupled to the other object, or whether there are one or more intervening objects between the one object and the other object. Also, directions (e.g., on top of, below, above, top, bottom, side, up, down, under, over, upper, lower, lateral, medial, vertical, horizontal, distal, proximal, etc.), if provided, are relative and provided solely by way of example and for ease of illustration and discussion and not by way of limitation. Furthermore, where reference is made herein to a list of elements (e.g., elements a, b, c), such reference is intended to include any one of the listed elements by itself, any combination of less than all of the listed elements, and/or a combination of all of the listed elements. Also, as used herein, the terms a, an, and one may each be interchangeable with the terms at least one and one or more. It should also be noted, that while the term step is used herein, that term may be used to simply draw attention to different portions of the described methods and is not meant to delineate a starting point or a stopping point, or order for any portion of the methods, or to be limiting in any other way.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/798,180 US20200390930A1 (en) | 2016-06-10 | 2020-02-21 | Systems and methods for treating a wound with wound packing |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662348698P | 2016-06-10 | 2016-06-10 | |
US15/620,531 US20170354754A1 (en) | 2016-06-10 | 2017-06-12 | Systems and methods for treating a wound with wound packing |
US16/798,180 US20200390930A1 (en) | 2016-06-10 | 2020-02-21 | Systems and methods for treating a wound with wound packing |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/620,531 Continuation US20170354754A1 (en) | 2016-06-10 | 2017-06-12 | Systems and methods for treating a wound with wound packing |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200390930A1 true US20200390930A1 (en) | 2020-12-17 |
Family
ID=60572123
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/620,531 Abandoned US20170354754A1 (en) | 2016-06-10 | 2017-06-12 | Systems and methods for treating a wound with wound packing |
US16/798,180 Pending US20200390930A1 (en) | 2016-06-10 | 2020-02-21 | Systems and methods for treating a wound with wound packing |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/620,531 Abandoned US20170354754A1 (en) | 2016-06-10 | 2017-06-12 | Systems and methods for treating a wound with wound packing |
Country Status (6)
Country | Link |
---|---|
US (2) | US20170354754A1 (en) |
EP (1) | EP3468625A4 (en) |
JP (1) | JP2019517566A (en) |
KR (1) | KR20190008415A (en) |
WO (1) | WO2017214631A1 (en) |
ZA (1) | ZA201808554B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200060997A (en) * | 2018-11-23 | 2020-06-02 | (주)메디코스바이오텍 | Pharmaceutical Composition for Treatment of Wounds |
US20210322228A1 (en) * | 2020-04-15 | 2021-10-21 | Annamarie Joseph | Sealskin Application System |
WO2022165365A1 (en) * | 2021-01-31 | 2022-08-04 | Global Health Solutions, Inc. | Powdered collagen wound care compositions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050234485A1 (en) * | 2001-02-16 | 2005-10-20 | Charles Seegert | Skin grafting devices and methods |
US20100010477A1 (en) * | 2008-07-08 | 2010-01-14 | Tyco Healthcare Group Lp | Portable Negative Pressure Wound Therapy Device |
WO2011135285A1 (en) * | 2010-04-27 | 2011-11-03 | Smith & Nephew Plc | Wound dressing |
US8092837B2 (en) * | 2007-04-27 | 2012-01-10 | Biomet Manufacturing Corp | Fibrin based glue with functionalized hydrophilic polymer protein binding agent |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535058A (en) * | 1982-10-01 | 1985-08-13 | Massachusetts Institute Of Technology | Characterization of oncogenes and assays based thereon |
US6322785B1 (en) * | 1999-03-02 | 2001-11-27 | Natrex Technologies | Methods and compositions for bone graft implants |
US20040078090A1 (en) * | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
US7473678B2 (en) * | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
EP3896152A1 (en) * | 2012-03-22 | 2021-10-20 | Avita Medical Ltd | Cell suspension and use thereof |
US20140186455A1 (en) * | 2012-12-31 | 2014-07-03 | Gino Bradica | Tissue repair system |
US10493134B2 (en) * | 2013-03-21 | 2019-12-03 | Collplant Ltd. | Compositions comprising collagen and PRP for tissue regeneration |
BE1023155B1 (en) * | 2015-06-30 | 2016-12-02 | Guido Wouters | Composition for wound healing |
-
2017
- 2017-06-12 JP JP2018564880A patent/JP2019517566A/en active Pending
- 2017-06-12 US US15/620,531 patent/US20170354754A1/en not_active Abandoned
- 2017-06-12 KR KR1020197000463A patent/KR20190008415A/en unknown
- 2017-06-12 EP EP17811164.7A patent/EP3468625A4/en not_active Withdrawn
- 2017-06-12 WO PCT/US2017/037058 patent/WO2017214631A1/en unknown
-
2018
- 2018-12-19 ZA ZA2018/08554A patent/ZA201808554B/en unknown
-
2020
- 2020-02-21 US US16/798,180 patent/US20200390930A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050234485A1 (en) * | 2001-02-16 | 2005-10-20 | Charles Seegert | Skin grafting devices and methods |
US8092837B2 (en) * | 2007-04-27 | 2012-01-10 | Biomet Manufacturing Corp | Fibrin based glue with functionalized hydrophilic polymer protein binding agent |
US20100010477A1 (en) * | 2008-07-08 | 2010-01-14 | Tyco Healthcare Group Lp | Portable Negative Pressure Wound Therapy Device |
WO2011135285A1 (en) * | 2010-04-27 | 2011-11-03 | Smith & Nephew Plc | Wound dressing |
Non-Patent Citations (4)
Title |
---|
Chahla et al. Concentrated Bone Marrow Aspirate for the Treatment of Chondral Injuries and Osteoarthritis of the Knee. The Orthopaedic Journal of Sports Medicine, 4(1), Jan. 13, 2016. p.1-8 (Year: 2016) * |
Debels et al. Dermal Matrices and Bioengineered Skin Substitutes: A Critical Review of Current Options. Plast Reconstr Surg Glob Open 2015;3:e284, p.63-72 (Year: 2015) * |
Friese. How to pack a severely bleeding wound. EMS Bleeding Control. EMS1. Feb. 23. p.1-4 (Year: 2016) * |
Leaper. Sharp technique for wound debridement. downloaded from www.worldwidewounds.com/2002/december/Leaper/Sharp-Debridement.html. p.1-5 (Year: 2002) * |
Also Published As
Publication number | Publication date |
---|---|
KR20190008415A (en) | 2019-01-23 |
ZA201808554B (en) | 2019-07-31 |
EP3468625A1 (en) | 2019-04-17 |
JP2019517566A (en) | 2019-06-24 |
EP3468625A4 (en) | 2020-02-12 |
WO2017214631A1 (en) | 2017-12-14 |
US20170354754A1 (en) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Serra et al. | Skin grafting for the treatment of chronic leg ulcers–a systematic review in evidence‐based medicine | |
US20200390930A1 (en) | Systems and methods for treating a wound with wound packing | |
CN103079577B (en) | The preparation technology of wound restoration agent compositions, pipe and device | |
Cervelli et al. | Tissue regeneration in loss of substance on the lower limbs through use of platelet-rich plasma, stem cells from adipose tissue, and hyaluronic acid | |
Balbo et al. | Platelet gel for the treatment of traumatic loss of finger substance | |
JP2015534945A (en) | Compositions and methods for mobilizing and localizing stem cells | |
KR20170088366A (en) | New standardizations & medical devices for the preparation of platelet rich plasma(prp) or bone marrow centrate(bmc) alone or in combination with hyaluronic acid | |
JP2023052341A (en) | Methods for isolation of platelets | |
JP2021106935A (en) | Composition for treating wound | |
TWI823964B (en) | Stem cell filtrate preparation and preparation method thereof | |
Zhang et al. | Repair of refractory wounds through grafting of artificial dermis and autologous epidermis aided by vacuum-assisted closure | |
US8728466B2 (en) | Treating burn injuries with reduced hypertrophic scarring | |
Price et al. | Skin repair technology | |
JPH11246420A (en) | Wound curing accelerator | |
Tolba et al. | Initial experience of face augmentation using fat graft-platlet rich plasma mix | |
SMITH | Amputation through lower third of leg for diabetic and arteriosclerotic gangrene | |
Bhattacharyya et al. | Gaenslen's split heel approach for the treatment of chronic osteomyelitis of the calcaneus: a series of three cases | |
RU2724275C1 (en) | Method of vacuum therapy of wounds with tissue defect by blood clot method | |
Tentolouris et al. | Methods of ulcer healing | |
Iorio et al. | Soft tissue reconstructive options for the ulcerated or gangrenous diabetic foot | |
Serdev et al. | Ultrasound Assisted Liposculpture–UAL: A Simplified Safe Body Sculpturing and Aesthetic Beautification Technique | |
Dalawai | Autologous Skin Cell Suspension For Accelerating Re-Epithelization Of Split Thickness Donor Sites | |
Ghatge et al. | nerve leads to sensory loss which in-turn enhances the risk oftrauma to the patient's feet, leading to chronic plantar ulceration. | |
Attinger | Soft tissue reconstructive options for the ulcerated or gangrenous diabetic foot | |
Khurram | A Prospective Study for Post Operative Split Skin Donor Site Management: Evaulation of Saline Moistened VS Conventional Semi-Occlusive Protocol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: CLYRA MEDICAL TECHNOLOGIES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIDEN, BROCK;BROWN, SPENCER;REEL/FRAME:054013/0462 Effective date: 20200930 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: SCION SOLUTIONS LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CLYRA MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:060370/0506 Effective date: 20220629 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |